Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973134 | 0.84 | ABL1 (0.49) | ABL1TRPV1SCN10A | |
| SCHEMBL28105100 | 0.75 | LMNA (0.66) | MAPTABL1TRPV1LMNASCN10A | |
| SCHEMBL2721728 | 0.73 | CA12 (0.59) | MAPTTRPV1LMNAHDAC3HDAC1 | |
| SCHEMBL28007802 | 0.71 | RAB9A (0.67) | MAPTTRPV1LMNA | |
| SCHEMBL20188661 | 0.71 | POLB (0.50) | MAPTLMNAHDAC3HDAC1HDAC2 | |
| SCHEMBL15391649 | 0.71 | ABL1 (0.61) | MAPTABL1 | |
| SCHEMBL4664426 | 0.70 | KDM4E (0.51) | TRPV1 | |
| SCHEMBL14965735 | 0.70 | MEN1 (0.65) | MAPTABL1TRPV1LMNAEPHX2 | |
| SCHEMBL3997038 | 0.70 | POLB (0.49) | MAPTLMNAEPHX2 | |
| SCHEMBL31560013 | 0.69 | SMN1; SMN2 (0.56) | TRPV1LMNAHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560564-B2 | Heterocyclic diamide invertebrate pest control agents | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060205748-A1 | Heterocyclic diamide invertebrate pest control agents | ANNIS GARY D | 2006-09-14 | — | — | US | disclosed |
| US-20040102324-A1 | Heterocyclic diamide invertebrate pest control agents | E.I. DU PONT DE NEMOURS AND COMPANY | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205748-A1 | Heterocyclic diamide invertebrate pest control agents | DDT, DBF4, C1S | MAPT 4481/4885ABL1 1997/4885TRPV1 449/4885 |
| US-20040102324-A1 | Heterocyclic diamide invertebrate pest control agents | DDT, DBF4, DDC | MAPT 4355/4885ABL1 2770/4885TRPV1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.